English: Description of Goods ethyl DL-mandelate; ethyl N-{2-[(acetylthio)methyl]-3-(o-tolyl)-1-oxopropyl}-L-methionate; indan-5-yl hydrogen phenylmalonate; Intermediate concentrate obtained from a genetically-modified Escherichia coli fermentation medium, containing human granulocytemacrophage colony-stimulating factor, used for the manufacture of medicaments of heading No. 30.02; Intermediate concentrate obtained from a genetically-modified Escherichia coli fermentation medium, containing human interferon alpha-2b, used for the manufacture of medicaments of heading No. 30.02; Intermediate concentrates obtained from a Micromonospora inyoensis fermentation medium used for the manufacture of the antibiotics sisomicin (INN) and netilmicin (INN); Intermediate concentrates obtained from a Micromonospora purpurea fermentation medium used for the manufacture of the antibiotics gentamicin sulfate (INNM) and isepamicin (INN); isopropyl 2,3-dihydro-1H-pyrrolizine-1-carboxylate; isopropyl[2-(piperazin-1-yl)-3-pyridyl]amine; L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-Lleucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-Lleucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine; magnesium bis[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4yl)methylamino]methanesulfonate; meso-N-benzyl-3-nitrocyclopropane-1,2-dicarboximide; methyl (2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate; methyl (2R,3S)-3-benzamido-2-hydroxy-3-phenylpropionate; methyl (4-nitrophenyl)-L-alaninate; methyl 1H-1,2,4-triazole-3-carboxylate; methyl 2-(3-nitrobenzylidene)-3-oxobutyrate; methyl 7-[(3RS)-3-hydroxy-5-oxocyclopent-1-enyl]heptanoate; N,N'-dibenzylethylenediammonium di(acetate); N-(5,6-dihydro-6-methyl-2-sulfamoyl-4H-thieno[2,3-b]thiopyran-4yl)acetamide 7,7-dioxide; N-(9-acetyl-6-oxo-6,9-dihydro-1H-purin-2-yl)acetamide; N-(benzyloxycarbonyl)-L-valine; N-(benzyloxycarbonyl)-S-phenyl-L-cysteine; N-(tert-butyl)-3-methylpyridine-2-carboxamide; N-[(R)-2-({(R)-2-[(2-adamantyloxycarbonyl)amino]-3-(1H-indol-3-yl)-2methyl-1-oxopropyl}amino)-1-phenylethyl]succinamic acid--1-deoxy-1methylamino-D-glucitol (1:1); N-[2-isopropylthiazol-4-ylmethyl(methyl)carbamoyl]-L-valine; N-{5-[(1,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)methylamino]2-thenoyl}-L-glutamic acid; omega-conotoxin M VIIA; p-nitrobenzyl (2R,5R,6S)-6-[(R)-1-hydroxyethyl]-3,7-dioxo-1azabicyclo[3.2.0]heptane-2-carboxylate; pentamethylene bis{3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4tetrahydro-2-isoquinolyl]propionate}--oxalic acid (1:2); pentyl chloroformate; potassium 1-(1-hydroxyethyl)-5-methoxy-2-oxo-1,2,5,6,7,8,8a,8boctahydroazeto[2,1-a]isoindole-4-carboxylate; purin-6(1H)-one; quinuclidin-3-ol; S-(benzothiazol-2-yl) (Z)-2-(2-aminothiazol-4-yl)-2-methoxy-
French: Dénomination des marchandises Concentré intermédiaire issu d'un milieu de fermentation d'Escherichia coli génétiquement modifié, contenant de l'interféron humain alpha-2b, destiné à la fabrication de médicaments de la position 30.02; Concentrés intermédiaires issus d'un milieu de fermentation de Micromonospora inyoensis, destinés à la fabrication des antibiotiques sisomicine (DCI) et nétilmicine (DCI); Concentrés intermédiaires issus d'un milieu de fermentation de Micromonospora purpurea, destinés à la fabrication des antibiotiques sulfate de gentamicine (DCIM) et isépamicine (DCI); 2,3-dihydro-1H-pyrrolizine-1-carboxylate d'isopropyle; isopropyl[2-(pipérazine-1-yl)-3-pyridyl]amine; L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-Lleucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-Lleucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine; bis[(2,3-dihydro-1,5-diméthyl-3-oxo-2-phényl-1H-pyrazole-4-yl) méthylamino]méthanesulfonate de magnésium; méso-N-benzyl-3-nitrocyclopropane-1,2-dicarboximide; (2R,3S)-2,3-époxy-3-(4-méthoxyphényl)propionate de méthyle; (2R,3S)-3-benzamido-2-hydroxy-3-phénylpropionate de méthyle; (4-nitrophényl)-L-alaninate de méthyle; 1H-1,2,4-triazole-3-carboxylate de méthyle; 2-(3-nitrobenzylidène)-3-oxobutyrate de méthyle; 7-[(3RS)-3-hydroxy-5-oxocyclopent-1-ényl]heptanoate de méthyle; di(acétate) de N,N'-dibenzyléthylènediammonium; 7,7-dioxyde de N-(5,6-dihydro-6-méthyl-2-sulfamoyl-4H-thiéno[2,3b]thiopyranne-4-yl)acétamide; N-(9-acétyl-6-oxo-6,9-dihydro-1H-purine-2-yl)acétamide; N-(benzyloxycarbonyl)-L-valine; N-(benzyloxycarbonyl)-S-phényl-L-cystéine; N-(tert-butyl)-3-méthylpyridine-2-carboxamide; acide N-[(R)-2-({(R)-2-[(2-adamantyloxycarbonyl)amino]-3-(1H-indole-3yl)-2-méthyl-1-oxopropyl}amino)-1-phényléthyl]succinamique-1désoxy-1-méthylamino-D-glucitol (1:1); N-[2-isopropylthiazole-4-ylméthyl(méthyl)carbamoyl]-L-valine; acide N-{5-[(1,4-dihydro-2-méthyl-4-oxoquinazoline-6-ylméthyl) méthylamino]-2-thénoyl}-L-glutamique; omega-conotoxine M VIIA; (2R,5R,6S)-6-[(R)-1-hydroxyéthyl]-3,7-dioxo-1-azabicyclo[3.2.0]heptane2-carboxylate de p-nitrobenzyle; bis{3-[1-(3,4-diméthoxybenzyl)-6,7-diméthoxy-1,2,3,4-tétrahydro-2isoquinolyl]propionate} de pentaméthylène--acide oxalique (1:2); chloroformiate de pentyle; 1-(1-hydroxyéthyl)-5-méthoxy-2-oxo-1,2,5,6,7,8,8a,8b-octahydroazéto[2,1-a]isoindole-4-carboxylate de potassium; purine-6(1H)-one; quinuclidine-3-ol; (Z)-2-(2-aminothiazole-4-yl)-2-méthoxyiminothioacétate de S(benzothiazole-2-yle); 4-[2-(5-méthylpyrazine-2-carboxamido)éthyl]benzènesulfonamide de sodium; [(1S,2S)-1-benzyl-2,3-dihydroxypropyl]carbamate de tert-butyle; [(1S,3S,4S)-4-amino-1-benzyl-3-hydroxy-5-phénylpentyl]carbamate de tert-butyle; [(4R,6R)-6-(cyanométhyl)-2,2-diméthyl-1,3-dioxolanne-4-yl]acétate de